Preparation, characterization and in vitro evaluation of PEGylated nanoliposomal containing etoposide on lung cancer

Abstract

Introduction and objective Lung cancer is the most common one in terms of outbreak and mortality. Since most modern treatments have many side effects, finding an effective and alternative therapy seems necessary. The present study aimed to determine the effect of PEGylated liposomal etoposide nanoparticles on the lung cancer (A-549 and Calu6 cell lines).Materials and methods The PEGylated liposomal etoposide nanoparticles were prepared by reverse-phase evaporation method. The particle size and zeta potential of the nanoparticles were measured by Zetasizer. The nanoparticle cytotoxicity was examined by MTT method. The vesicular drug release pattern was examined by dialysis method. The amount of loaded drug and the encapsulation efficiency (EE) was also measured and calculated. Apoptosis test was performed using flow cytometry with Annexin V kit.Results The mean particle size, size distribution, and zeta potential of PEGylated liposomal etoposide nanoparticles were 122.5 ± 4.8 nm, 0.252 ± 0.12 and −13.7 ± 0.51 mv, respectively. The etoposide release in prepared formulations was detected to be about 15.64% after 50 hr. The cytotoxic effect of etoposide nanoparticles on lung cancer A-549 and Calu6 cell lines showed more anti-tumour activity compared to the free drug used.Conclusion The results showed that the PEGylated liposomal nanoparticles were used as a suitable nanocarrier for etoposide injection. It was also found that the drug effect on the nanodrug formulations was higher than that of the free drug.

Keywords

• PEGylated liposomal nanoparticles
• reverse-phase evaporation
• MTT
• lung cancer
• etoposide